Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight rating on the shares. The firm, which refreshed its model for Q4 results, notes that multiple clinical updates are anticipated across the pipeline in 2025 and contends that NX-5948 “remains the key driver for the stock.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift
- Nurix Therapeutics Reports Solid Progress and Strong Pipeline
- Nurix Therapeutics price target raised to $27 from $26 at RBC Capital
- Nurix Therapeutics reports Q4 EPS (75c), consensus (68c)
- Nurix Therapeutics price target raised to $36 from $34 at Stifel